Literature DB >> 27157052

Longitudinal Follow-up of Lung Cancer Resection From the Society of Thoracic Surgeons General Thoracic Surgery Database in Patients 65 Years and Older.

Felix G Fernandez1, Anthony P Furnary2, Andrzej S Kosinski3, Mark W Onaitis3, Sunghee Kim3, Daniel Boffa4, Patricia Cowper3, Jeffrey P Jacobs5, Cameron D Wright6, Joe B Putnam7.   

Abstract

BACKGROUND: The Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) does not capture long-term survival after lung cancer surgery. Our objective was to provide longitudinal follow-up to the STS GTSD through linkage to Centers for Medicare and Medicaid Services (CMS) data for patients 65 years of age or older.
METHODS: Lung cancer operations reported in the STS GTSD from 2002 through 2012 were linked to CMS data for patients 65 years of age or older using variables common to both databases with a deterministic matching algorithm. Mortality data were abstracted for each linked patient from the CMS data. The Kaplan-Meier method was used to estimate long-term survival for lung cancer surgery patients based on tumor stage.
RESULTS: From 2002 through 2012, 60,089 lung cancer resections were identified in the GTSD, and 37,009 (61.7%) were in patients 65 years or older. Of these, 26,055 of 37,099 lung cancer resections (70%) in patients 65 years or older were successfully linked to CMS data. Failure to link was most commonly related to having a health maintenance organization or commercial insurance as the primary payer: 40.5% (5,290 of 13,065) of such patients were not linked from 2009 to 2012 (years payer data available). Median survival after lung cancer resection was 6.7 years for pathologic stage I, 3.5 years for stage II, 2.4 years for stage III, and 2.2 years for stage IV.
CONCLUSIONS: The CMS data complement the STS GTSD data by enabling examination of long-term survival and resource utilization in patients 65 years or older. Linked data from the STS GTSD and the CMS will allow for longitudinal analyses of comparative effectiveness among different surgical approaches for the treatment of lung cancer.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27157052     DOI: 10.1016/j.athoracsur.2016.03.034

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

Review 1.  Blazing new trails: initial efforts to create a joint Society of Thoracic Surgeons-European Society of Thoracic Surgeons (STS-ESTS) dataset.

Authors:  Christopher W Seder
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Moving beyond disease-focused decision making: understanding competing risks to personalize lung cancer treatment for older adults.

Authors:  Lauren J Taylor; James D Maloney
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

3.  Surgically Managed Clinical Stage IIIA-Clinical N2 Lung Cancer in The Society of Thoracic Surgeons Database.

Authors:  Daniel Boffa; Felix G Fernandez; Sunghee Kim; Andrzej Kosinski; Mark W Onaitis; Patricia Cowper; Jeffrey P Jacobs; Cameron D Wright; Joe B Putnam; Anthony P Furnary
Journal:  Ann Thorac Surg       Date:  2017-05-17       Impact factor: 4.330

4.  Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease.

Authors:  Nichole T Tanner; Lin Dai; Brett C Bade; Mulugeta Gebregziabher; Gerard A Silvestri
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

5.  Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer.

Authors:  Jacob Y Shin; Ja Kyoung Yoon; Gaurav Marwaha
Journal:  Lung       Date:  2018-03-17       Impact factor: 2.584

6.  Twenty-Year Survival of Patients Operated on for Non-Small-Cell Lung Cancer: The Impact of Tumor Stage and Patient-Related Parameters.

Authors:  Olivier Schussler; Antonio Bobbio; Hervé Dermine; Audrey Lupo; Diane Damotte; Yves Lecarpentier; Marco Alifano
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.